Loading…

Browse All Grants

20,252 grants found

Filters
Reset

Showing 1,4811,500 of 20,252 grants

Active NON-SBIR/STTR RPGS
A soft magnetoelastic microneedle patch for rapid skin cancer screening
NATIONAL CANCER INSTITUTE University of California Los Angeles United States 2024 – 2029

PROJECT SUMMARY Over 2.5 million skin cancers are diagnosed annually in the United States, more than all other forms of cancers combined. Early diagnosis is critical; thus, we prop...

$3.51M
USD
Active NON-SBIR/STTR RPGS
Mechanism and functional consequences of dietary lipids in lineage specification and tumor growth in oncohistone gliomas
NATIONAL CANCER INSTITUTE Dana-Farber Cancer Inst United States 2024 – 2029

PROJECT SUMMARY: Mechanism and functional consequences of dietary lipids in lineage specification and tumor growth in oncohistone gliomas Diffuse midline gliomas (DMGs) are the mos...

$7.22M
USD
Active NON-SBIR/STTR RPGS
Diet-mediated regulation of fatty acid saturation impacts cancer progression and therapy responses.
NATIONAL CANCER INSTITUTE Van Andel Research Institute United States 2024 – 2029

Project Summary/Abstract Many “anti-cancer” diets are promoted in popular culture for cancer prevention and treatment, reflecting the enthusiasm of patients, clinicians, and resear...

$7.97M
USD
Active NON-SBIR/STTR RPGS
The Role of HA Remodeling and Mesenchymal Transitions in Glioblastoma
NATIONAL CANCER INSTITUTE University of Louisville United States 2024 – 2027

PROJECT SUMMARY Glioblastoma (GBM) is a deadly disease with no effective therapy and is associated with one of the worst 5-year survival rates of all human cancers. Current treatme...

$4.7M
USD
Active NON-SBIR/STTR RPGS
Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder Cancer
NATIONAL CANCER INSTITUTE Dana-Farber Cancer Inst United States 2024 – 2029

PROJECT SUMMARY Platinum-based chemotherapy regimens improve survival for patients with muscle-invasive (MIBC) and metastatic bladder cancer (BC), and this approach remains the the...

$7.37M
USD
Active NON-SBIR/STTR RPGS
Transcatheter Intra-Arterial Delivery of Oriented Anti-PD-L1 Immune checkpoint inhibitors Immobilized Nanocarriers for Local Combination Immunotherapy of Hepatocellular Carcinoma
NATIONAL CANCER INSTITUTE Northwestern University At Chicago United States 2024 – 2029

PROJECT SUMMARY Hepatocellular carcinoma (HCC) is the 5th most common malignancy in the world and the 4th leading cause of cancer death in the US. Resection and transplantation are...

$3.57M
USD
Active NON-SBIR/STTR RPGS
Enrichment for Tumor-derived Cell-free EBV DNA: Towards a Diagnostic Assay for Endemic Burkitt Lymphoma
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2024 – 2029

PROJECT SUMMARY Endemic Burkitt lymphoma (eBL) outcomes in children with advanced stage disease are markedly inferior to those in children with early-stage disease. eBL is one of t...

$3.58M
USD
Completed NON-SBIR/STTR RPGS
Designing inducible chemotactic beacons for enhanced trafficking of CAR T cells to solid tumors
NATIONAL CANCER INSTITUTE Seattle Children'S Hospital United States 2024 – 2026

ABSTRACT CAR T cell immunotherapy has proven to be a real tour de force in treating refractory hematologic malignancies, and is being explored for treatment of solid tumors. Howeve...

$2.3M
USD
Active NON-SBIR/STTR RPGS
Profiling and perturbing the inheritance of drug-induced metabolic states in cancer with Inheritance-Seq
NATIONAL CANCER INSTITUTE Broad Institute, Inc United States 2024 – 2027

Non-genetic acquired resistance has been implicated in the therapy failure of multiple cancer types. Therefore, there have been significant efforts to uncover the mechanisms regula...

$2.07M
USD
Completed TRAINING, INDIVIDUAL
DUSP2 in Negative Regulation of Cytotoxic T Cell Responses to Immunotherapy
NATIONAL CANCER INSTITUTE Mayo Clinic Rochester United States 2024 – 2025

ABSTRACT Durable tumor regression by immune checkpoint blockade (ICB) has been observed in a small cohort of cancer patients, but ICB efficacy varies widely on an individual basis....

$489.7K
USD
Active TRAINING, INDIVIDUAL
Mechanisms of Macrophage-Mediated Immune Evasion in Residual Tumors
NATIONAL CANCER INSTITUTE Duke University United States 2024 – 2027

Abstract Oncogene targeted therapies offer a safe and effective approach to suppress cancer since these drugs spare healthy tissues by selectively targeting driver mutations in can...

$422K
USD
Completed TRAINING, INDIVIDUAL
Examining Physical Activity Promotion Intervention Outcomes, Barriers and Facilitators in Breast Cancer Survivors with Fatigue
NATIONAL CANCER INSTITUTE Northwestern University At Chicago United States 2024 – 2026

Project Summary/Abstract Breast cancer is the most diagnosed cancer in women in the United States, and the population of breast cancer survivors (BCS) is growing. Cancer-related fa...

$441.9K
USD
Completed SBIR-STTR RPGS
Accurate prognosis and prediction of clinical benefits of adjuvant therapy for early-stage non-small cell lung cancer
NATIONAL CANCER INSTITUTE Sostos Llc United States 2024 – 2025

Project Summary Sostos, LLC has developed a qRT-PCR-based microfluidic 7-gene assay (CATOS-LU) that predicts recurrence or progression to metastasis of non-small cell lung cancer (...

$4M
USD
Active TRAINING, INDIVIDUAL
High-Throughput Measurements of RNA-Mediated Regulation of Gene Expression and Oncogenesis
NATIONAL CANCER INSTITUTE Stanford University United States 2024 – 2027

Project Summary Dysregulation of RNA-binding protein (RBP)-RNA interactions impacts the coordination of RNA fate with severe implications for human health. RBPs interact directly w...

$512.4K
USD
Active TRAINING, INDIVIDUAL
Next-generation diagnostic approaches for HER2-low breast cancer and trastuzumab deruxtecan therapy
NATIONAL CANCER INSTITUTE Yale University United States 2024 – 2027

The current assays for assessing HER2 were “fit-for-purpose” (over 25-years ago) to identify HER2 overexpression/gene amplification and are not built to subclassify unamplified HER...

$339.6K
USD
Active TRAINING, INDIVIDUAL
Defining protein translation dynamics in cancers with differential Myc expression
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2024 – 2027

PROJECT SUMMARY Gene amplification of the oncogene Myc is associated with increased metastasis, resistance to treatment, and overall poor prognosis and survival across several canc...

$539.7K
USD
Active TRAINING, INDIVIDUAL
Elucidating the Role of AIRE and Tumor Associated Aire-expressing Cells in Tumor Growth and Immune Evasion
NATIONAL CANCER INSTITUTE University of California, San Francisco United States 2024 – 2027

PROJECT SUMMARY/ABSTRACT Autoimmune Regulator gene (AIRE) prevents autoimmunity by promoting thymic deletion of self-reactive T cells. While most studied in the thymus, AIRE is als...

$414.9K
USD
Active TRAINING, INDIVIDUAL
Understanding and exploiting apoptotic dysregulation in ovarian cancer
NATIONAL CANCER INSTITUTE Harvard School of Public Health United States 2024 – 2027

PROJECT SUMMARY/ABSTRACT Death rates have decreased across many cancer types owing to improved early detection and treatment methods, but remained largely stagnant for ovarian canc...

$447.2K
USD
Completed TRAINING, INDIVIDUAL
Targeting the RNA helicase DDX6 in acute myeloid leukemia
NATIONAL CANCER INSTITUTE Baylor College of Medicine United States 2024 – 2025

PROJECT SUMMARY Acute myeloid leukemia (AML) is an aggressive blood cancer characterized by the accumulation of abnormal myeloid progenitors arrested in differentiation. It is the...

$767.6K
USD
Active TRAINING, INDIVIDUAL
Unlocking the Diagnostic and Prognostic Potential of 5hmC in Urine cfDNA: Characterization of Genome-wide Landscape in Healthy Urine and Biomarker Development in Localized Bladder Cancer
NATIONAL CANCER INSTITUTE University of Chicago United States 2024 – 2028

PROJECT SUMMARY/ABSTRACT Epigenetic modifications play a crucial role in mammalian development, cellular differentiation, and disease, with 5-methylcytosine (5mC) being the most we...

$539.7K
USD